Evaluating a molecular screening protocol for fetal Down syndrome
碩士 === 長庚大學 === 醫學生物技術研究所 === 94 === Trisomy 21 is the most frequent chromosome aneuploidy with the incidence of approximately 1 in 900 newborns. The rapid prenatal diagnosis of chromosome aneuploidies have been successful through fluorescence PCR (F-PCR) assay combined with short tandem repeat (STR...
Main Authors: | Ching Ping Yeh, 葉菁萍 |
---|---|
Other Authors: | Da Chang Chu |
Format: | Others |
Language: | zh-TW |
Published: |
2006
|
Online Access: | http://ndltd.ncl.edu.tw/handle/29099191303779259300 |
Similar Items
-
The Significance of Apolipoprotein E Measurement in the Screening of Fetal Down Syndrome
by: Angelika Buczyńska, et al.
Published: (2020-12-01) -
Brief Communication: Maternal Plasma Autoantibodies Screening in Fetal Down Syndrome
by: Karol Charkiewicz, et al.
Published: (2016-01-01) -
Maternal Plasma and Amniotic Fluid Chemokines Screening in Fetal Down Syndrome
by: Piotr Laudanski, et al.
Published: (2014-01-01) -
Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
by: Chanane Wanapirak, et al.
Published: (2019-11-01) -
The role of the fetal microenvironment in abnormal fetal haematopoiesis in Down syndrome
by: O'Connor, David
Published: (2014)